We compare the consequences of DHX9 suppression in p53-wildtype and p53-deficient settings in three different ex vivo models: mouse lymphomas, mouse embryonic fibroblasts (MEFs), and human colon cancer cells. This evidence concerns the gene TP53 and malignant colon neoplasm.